Citations

Clear

3057 citation(s) found for "Cd, Johnson".

Pushing the agenda for intravenous push administration in outpatient parenteral antimicrobial therapy
Johnson, Tanner M , Webster, Leah C. Whitman , Mehta, Meera, Johnson, Jessica E. , Cortés-Penfield, Nicolás , Whitman Webster, Leah C, Johnson, Tanner M , Webster, Leah Whitman , Rivera, Christina G.

Mayo Clinic

Therapeutic Advances in Infectious Disease | August 16, 2023 | Volume: 10 | Issue: No issue available | Pages: No page available

10.1177/20499361231193920 | PMID 37600976 Get It

Intravenous push (IVP) antimicrobial administration refers to rapid bolus infusion of medication. This drug delivery method offers improved patient convenience, superior patient and nursing satisfaction, and cost savings when used in outpatient parenteral antimicrobial therapy (OPAT). Antimicrobial agents must demonstrate optimal physiochemical and pharmacologic characteristics, as well as sufficient syringe stability, to be administered in this manner. Additionally, impacts on medication tolerability, patient safety, and effectiveness must be considered. This narrative review summarizes the available data and practical implications of IVP administration of antimicrobials in the OPAT setting.
Viral infection in the brain induces priming and maintenance of a novel antigen specific CD8 T cell population within the bone marrow that dysregulates the stem cell niche
Wolf, Delaney, Tritz, Zachariah Peter , Reesman, Rachael , Rangel, Frances A, Bamkole, Michael , Maynes, Mark A, Hansen, Michael J. , Johnson, Aaron J. , Wolf, Delaney M. , Tritz, Zachariah P. , Pfaller, Christian K. , Maynes, Mark A , Jin, Fang , Fain, Cori E. , Johnson, Aaron J. , Ayasoufi, Katayoun

Mayo Clinic

The Journal of Immunology | August 10, 2023 | Volume: 210 | Issue: Supplement_1 | Pages: 226.16-226.16

10.4049/jimmunol.210.supp.226.16 Get It

Abstract Bone marrow is a primary immune organ responsible for stem cell maintenance and hematopoiesis. While the bone marrow niche is mainly studied in the context of hematopoiesis, aging, and mechanisms underlying stem cell and plasma cell survival, changes of the niche during brain viral infections and primary T cell responses is unknown. Intracranial infection with the neurotropic Theiler’s Murine Encephalomyelitis Virus (TMEV) results in an acute infection in the C57BL/6 mouse which is cleared 30 days post infection due to generation of an antigen specific CD8 T cell response raised against the immunodominant epitope VP2121–130. We determined that 7–10% of CD8 T cells present in the sternal and femoral bone marrows and 15–20% in the cranial bone marrow were antigen specific 7 days post intracranial TMEV infection. Over 70% of these CD8 T cells were located outside of the vasculature as determined by IV labeling. Importantly, continuous treatment with FTY720, which sequesters T cells outside of the blood, did not eliminate antigen specific CD8 T cells in any bone marrow compartment. CD8 T cells in the bone marrow established durable memory following viral clearance and were reactivated upon cognate antigen reencounter. Both acute TMEV infection and antigen specific reactivation caused an increase in lineage−, Sca-1+, ckit+ (LSK) cells in the bone marrow. This LSK dysregulation was abrogated upon CD8 T cell depletion. We conclude that brain viral infections induce in situ effector and memory T cell responses within the bone marrow compartment. Both acute and memory recall CD8 T cell responses cause stem cell dysregulation. Our data hence paves the way for crucial studies of bone marrow resident antigen specific CD8 T cells in health and disease. Supported by grants from NIH (K99NS117799-01A1 (KA), R01NS103212 (AJJ), and RF1NS122174(AJJ)
Cell-specific MHC class I deletion on CD11c+ APCs abrogates CD8 T Cell infiltration into the brain
Maynes, Mark Andrew, Wolf, Delaney, Tritz, Zachariah P. , Bamkole, Michael , Hansen, Michael J. , Johnson, Aaron J. , Maynes, Mark A , Fain, Cori E. , Ayasoufi, Katayoun , Wolf, Delaney M. , Jin, Fang , Johnson, Aaron J.

Mayo Clinic

The Journal of Immunology | August 10, 2023 | Volume: 210 | Issue: Supplement_1 | Pages: 221.34-221.34

10.4049/jimmunol.210.supp.221.34 Get It

Abstract Cerebral malaria (CM) is a severe complication of P. falciparum infection and a leading cause of death, globally. Plasmodium berghei ANKA (PbA) infection of C57BL/6 mice serves as a murine model of CM called experimental cerebral malaria (ECM) due to the neurological and neuropathological features that simulate the infection of human CM. A putative mechanism of disease in human CM requires CD8 T cell to infiltration into the brain and blood-brain barrier disruption. The specific antigen-presenting cell type(s) that prime this CNS infiltrating CD8 T cell response capable of inducing lethal blood-brain barrier disruption has not been defined. To answer this, single class I expressing Kb loxP transgenic mice were generated. Crossing these mice to class I deficient CD11c-cre or LysM-cre mice created the LysM-cre Kb cKO and CD11c-cre Kb cKO mice, respectively. PbA infected Kb loxP and LysM-cre Kb cKO were susceptible to ECM. In contrast, CD11c-cre Kb cKO mice survived acute PbA infection and avoided neurological manifestations. We therefore employed spectral flow cytometry to analyze splenocytes and brain infiltrating immune cells during acute PbA infection in these genotypes. We observed a reduction in activated CD8 T cells in the spleens of PbA infected CD11c-cre Kb cKO mice versus the Kb loxP mice and the LysM-cre Kb cKO. This reduced peripheral CD8 T cell activation in PbA infected CD11c-cre Kb cKO mice also corresponded with reduced brain infiltration of CD8 T cells. We conclude a CD11c+ APC is therefore required for priming and potentially recruitment of CD8 T cells to the brain during lethal ECM pathology. 5R01NS103212-06
Circulating cell-free DNA directly inhibits T cell function and contributes to peripheral immunosuppression in experimental GBM
Reesman, Rachael , Rangel, Frances A, Gulbicki, Lauren R, Tritz, Zachariah P. , Hansen, Michael, Johnson, Aaron J. , Ayasoufi, Katayoun , Wolf, Delaney M. , Gulbicki, Lauren , Jin, Fang , Fain, Cori E. , Pfaller, Christian K. , Johnson, Aaron J

Mayo Clinic

The Journal of Immunology | August 10, 2023 | Volume: 210 | Issue: Supplement_1 | Pages: 245.24-245.24

10.4049/jimmunol.210.supp.245.24 Get It

Abstract Glioblastoma (GBM) is an incurable brain cancer that is associated with severe peripheral immunosuppression. This immunosuppression is a critical barrier to patient survival and the success of immunotherapies. C57BL/6 mice harboring GL261 gliomas present with the hallmark features of peripheral immunosuppression observed in GBM patients, including T cell lymphopenia. We determined that peripheral immunosuppression involves release of non-steroidal soluble factors with large molecular weight that are found in sera of glioma-bearing mice. Sera of glioma-bearing mice inhibits T cell proliferation ex vivo. To determine the identity of the immunosuppressive molecules in serum, we used two parallel approaches: 1.) evaluation of abundant macromolecules and 2.) proteomics analysis using tandem mass tag mass-spectrometry (TMT-MS). We determined that serum of glioma-bearing mice contains significantly higher levels of cell free DNA (cfDNA) compared to controls. TMT-MS identified histones as a highly abundant protein in serum, further implicating DNA-histone complexes as top candidates. DNAse treatment of sera isolated from GL261 glioma-bearing mice reduced the suppressive effect on T cell proliferation. We next performed T cell proliferation assays in the presence of pure cfDNA isolated from sera of glioma-bearing mice while genomic DNA was used as control. cfDNA from serum potently inhibited T cell proliferation while control genomic DNA did not. These results were AIM2 independent implicating a novel pathway of DNA sensing in T cells. We contend that cfDNA induces immunosuppressive effects in experimental GBM. Devising strategies to reverse immunosuppression through targeting cfDNA could improve outcomes in GBM patients. Supported by grants from NIH (K99NS117799-01A1 (KA), R01NS103212 (AJJ), and RF1NS122174(AJJ) and Brains Together for a Cure Foundation (KA).
Time Course scRNAseq Analysis Reveals Mechanisms of Impaired Lung Recovery Post Influenza Infection during Aging: Zooming into Macrophages
Wu, Yue , Gao, Xiaochen , Li, Ying , Fain, Cori E. , Johnson, Aaron J. , Tang, Jinyi , Li, Chaofan , Zhu, Bibo , Santos, Gislane de Almeida , Narasimhan, Harish , Zhang, Ruixuan , Ayasoufi, Katayoun , Johnson, Aaron J. , Dong, Haidong , Sun, Jie

Mayo Clinic

The Journal of Immunology | August 10, 2023 | Volume: 210 | Issue: Supplement_1 | Pages: 71.24-71.24

10.4049/jimmunol.210.supp.71.24 Get It

Abstract Aging is considered to be a major risk factor for host morbidity and mortality upon acute respiratory virus infections. To better elucidate the immune determinants of viral pathogenesis during aging, we chronological characterized lung cellular and molecular profiles following influenza virus (PR8) infection in young or aged mice till 60 days post infection. Time-course scRNAseq coupled with high dimensional flow cytometry enabled the description of changes in both immune and stromal compartment between young and aged hosts. We further zoomed into the myeloid compartment and focused on the dynamic responses of lung macrophages given their complex roles in viral pathogenesis, tissue repair and lung fibrosis. Enlarged Monocyte-derived Macrophage (MoM) population as well as decreased resident-Alveolar Macrophage (AM) population were observed in the aged mice when compared to those of the young mice. Despite the self-sustain nature of AMs during homeostasis, it has been reported that Ly6Chi monocytes can gain AM identity following severe lung damage like influenza virus infection. We found that the gain of AM identity from monocytes was abrogated in the aged hosts, which likely contributed to the age-associated impairment in lung recovery after influenzas virus infection. Additionally, trajectory analysis with scRNAseq allowed us to identify IFNα/γ signaling to be potential pathways contributing to such defect. This notion is also supported by elevated IFNγ level in BAL from the aged host during lung recovery. Our results thus have improved our understanding on the cellular and molecular mechanisms by which aged hosts exhibit severe diseases and delayed recovery after respiratory viral infection.
Dissecting the role of H-2Db class I molecule in the development of brain atrophy during Theiler’s murine encephalomyelitis virus (TMEV) infection
Wininger, Katheryn M. , Tritz, Zachariah Peter , Wolf, Delaney, Hansen, Michael J. , Johnson, Aaron J. , Goddery, Emma N. , Ayasoufi, Katayoun , Tritz, Zachariah P. , Wolf, Delaney M. , Jin, Fang , Johnson, Aaron J.

Mayo Clinic

The Journal of Immunology | August 10, 2023 | Volume: 210 | Issue: Supplement_1 | Pages: 59.10-59.10

10.4049/jimmunol.210.supp.59.10 Get It

Abstract Brain atrophy is a common feature of many neurological diseases as diverse as Alzheimer’s disease, cerebral palsy, Huntington’s disease, multiple sclerosis, epilepsy, encephalitis, neurosyphilis, neuroAIDS, and Covid-19 infection. We have developed a murine model of brain atrophy using the Theiler’s murine encephalomyelitis virus (TMEV) infection mouse model of multiple sclerosis. In this study, we investigated the contribution of the MHC class I molecule, H-2Db, in generating an immune response associated with the onset of brain atrophy using mice with a C57BL/6 background. The H-2DbClass I molecule not only contributed to significantly more ventricular enlargement in a T2-weighted MRI at 45 d.p.i., but this ventricular enlargement correlated to CD8 T cell infiltration. To further define the cellular and molecular mechanisms of MHC class I molecules in TMEV induced brain atrophy we investigated the cell specific contribution of brain resident antigen presenting cells (APCs) in ventricular atrophy. We developed novel bi-transgenic mouse lines with tamoxifen induced conditional ablation of the H-2Db class I molecule in Cx3CR1+ brain resident myeloid cells. Cx3CR1cre+/Db Lox P mice presented with significantly less ventricular atrophy at 45 d.p.i., compared to cre- littermates along with a decrease in CD8 T cell infiltration. These results strongly imply that antigen presentation by H-2Db on myeloid cells, at least in part is responsible for the development of brain atrophy and provided insight into the molecular mechanism of this poorly understood neuropathology. NS103212, NS122174
Antigen-specific reactivation of brain tissue resident memory CD8 T cells directly induces severe neuroinflammation and blood-brain-barrier disruption
Jin, Fang, Bamkole, Michael , Tritz, Zachariah Peter , Maynes, Mark A, Hansen, Michael, Fain, Cori E. , Johnson, Aaron J. , Ayasoufi, Katayoun , Wolf, Delaney M. , Tritz, Zachariah P. , Maynes, Mark A , Pfaller, Christian K. , Johnson, Aaron J.

Mayo Clinic

The Journal of Immunology | August 10, 2023 | Volume: 210 | Issue: Supplement_1 | Pages: 59.31-59.31

10.4049/jimmunol.210.supp.59.31 Get It

Abstract Intracranial infection with neurotropic Theiler’s Murine Encephalomyelitis Virus induces robust generation of brain TRMs against the immunodominant antigen, VP2121–130, following viral clearance in C57BL/6 mice. While the presence of TRMs in the brain is documented, neurological consequences of TRM reactivation and their causal role in neuropathology remain understudied. We disabled peripheral CD8 T cells via anti CD8 depleting strategies and FTY720 treatment to determine the causal link between brain TRM reactivation and neuropathology. We depleted peripheral T cells and then administrated VP2 peptide IV to reactivate TRMs 60–200 days post infection as this elegant technique isolates responses of brain TRMs away from other branches of memory. We used state-of-the-art flow cytometry and MRI analysis to evaluate neurological consequences of TRM reactivation. TRM reactivation induced severe neuroinflammation in the brain as evident by infiltration of myeloid cells and blasting of T cells. MRI detected gadolinium leakage marking severe blood-brain-barrier (BBB) disruption when brain TRMs were reactivated. Depletion of peripheral CD8 T cells with low-dose anti CD8 antibodies or their sequestration via FTY720 did not alter neuroinflammation indicating brain TRM reactivation causally initiates neuropathology. Confirming this, tissue depletion of all TRMs in the brain using high-dose anti CD8 antibodies prevented both neuroinflammation and neuropathology. Hence, TRM reactivation causes severe neuroinflammation and BBB disruption from within the brain independently of peripheral T cells. Targeting brain TRM reactivation is a novel potential therapeutic for patients with many acute and chronic neurological diseases. Supported by grants from NIH (K99NS117799-01A1 (KA), R01NS103212 (AJJ), and RF1NS122174(AJJ)
PB2128: CLINICAL CONSENSUS ON FIRST-LINE (1L) TREATMENTS FOR TRANSPLANT-INELIGIBLE (TIE) PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): DELPHI PANEL OF US HEMATOLOGISTS AND ONCOLOGISTS
Voelker, Jennifer , Homan, Trevor, Kaila, Shuchita, Medhekar, Rohan , Wilcock, Jessica, Karakusevic, Anna , Cochrane, J.C., Bridge, Daisy, Perry, Richard , Fonseca, Rafaël , Rossi, Adriana , Cochrane, James, Perry, Richard, Davies, Faith E.

Mayo Clinic

HemaSphere | August 9, 2023 | Volume: 7 | Issue: S3 | Pages: e8448894

10.1097/01.hs9.0000975276.84488.94 Get It

MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP -Deleted Cancer
Engstrom, Lars D. , Aranda, Ruth , Waters, Laura , Moya, Krystal , Bowcut, Vickie , Vegar, Laura , Trinh, David , Hebbert, Allan , Smith, Christopher R. , Kulyk, Svitlana , Lawson, J. David , He, Leo , Hover, Laura D. , Hallin, Jill , Vanderpool, Darin , Briere, David M. , Blaj, Alice , Arbour, Kathryn C. , Jänne, Pasi A. , Papadopoulos, Kyriakos P. , Henry, Jason T. , Leventakos, Konstantinos , Christensen, James G. , Shazer, Ronald , Olson, Peter , Fernandez-Banet, Julio , Hallin, Jill , Vanderpool, Darin , Briere, David M , Blaj, Alice , Marx, Matthew A , Rodon, Jordi , Offin, Michael , Arbour, Kathryn C , Johnson, Melissa L , Kwiatkowski, David J. , Jänne, Pasi A , Haddox, Candace L , Papadopoulos, Kyriakos P , Henry, Jason T , Leventakos, Konstantinos , Christensen, James G , Shazer, Ronald , Olson, Peter , Johnson, Melissa L. , Haddox, Candace L.

Mayo Clinic

Cancer Discovery | August 8, 2023 | Volume: 13 | Issue: 11 | Pages: 2412-2431

10.1158/2159-8290.cd-23-0669 | PMID 37552839 Get It

Abstract Previous studies implicated protein arginine methyltransferase 5 (PRMT5) as a synthetic lethal target for MTAP-deleted (MTAP del) cancers; however, the pharmacologic characterization of small-molecule inhibitors that recapitulate the synthetic lethal phenotype has not been described. MRTX1719 selectively inhibited PRMT5 in the presence of MTA, which is elevated in MTAP del cancers, and inhibited PRMT5-dependent activity and cell viability with >70-fold selecti­vity in HCT116 MTAP del compared with HCT116 MTAP wild-type (WT) cells. MRTX1719 demonstrated dose-dependent antitumor activity and inhibition of PRMT5-dependent SDMA modification in MTAP del tumors. In contrast, MRTX1719 demonstrated minimal effects on SDMA and viability in MTAP WT tumor xenografts or hematopoietic cells. MRTX1719 demonstrated marked antitumor activity across a panel of xenograft models at well-tolerated doses. Early signs of clinical activity were observed including objective responses in patients with MTAP del melanoma, gallbladder adenocarcinoma, mesothelioma, non–small cell lung cancer, and malignant peripheral nerve sheath tumors from the phase I/II study. Significance: PRMT5 was identified as a synthetic lethal target for MTAP del cancers; however, previous PRMT5 inhibitors do not selectively target this genotype. The differentiated binding mode of MRTX1719 leverages the elevated MTA in MTAP del cancers and represents a promising therapy for the ∼10% of patients with cancer with this biomarker. See related commentary by Mulvaney, p. 2310. This article is featured in Selected Articles from This Issue, p. 2293
S202: CARTITUDE-1 FINAL RESULTS: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL IN HEAVILY PRETREATED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Munshi, Nikhil C. , Martin, Tom, Deol, Abhinav , Htut, Myo , O’Donnell, Elizabeth , Jackson, Carolyn C. , Yeh, Tzu‐Min, Banerjee, Arnob , Zudaire, Enrique, delCorral, Christopher, Pacaud, Lida , Usmani, Saad Z. , Berdeja, Jesús G. , Jakubowiak, Andrzej , Agha, Mounzer , Cohen, Adam D. , Lesokhin, Alexander M. , Lin, Yi , Madduri, Deepu , Jagannath, Sundar

Mayo Clinic

HemaSphere | August 8, 2023 | Volume: 7 | Issue: S3 | Pages: e6102468

10.1097/01.hs9.0000967720.61024.68 Get It